Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27277637 | 0.83 | ADORA1 (0.56) | ADORA1ADORA3ADORA2ASMN1; SMN2HRH3 | |
| SCHEMBL5235398 | 0.77 | PDE7A (0.43) | ADORA1ADORA3NR1D1ADORA2AHRH3 | |
| SCHEMBL5237026 | 0.74 | ADORA1 (0.46) | ADORA1ADORA3NR1D1ADORA2ALMNA | |
| SCHEMBL5321396 | 0.73 | ADORA1 (0.39) | ADORA1ADORA3NR1D1ADORA2ASMN1; SMN2 | |
| SCHEMBL25077760 | 0.73 | ADORA1 (0.50) | ADORA1ADORA3ADORA2ASMN1; SMN2HRH3 | |
| SCHEMBL18346735 | 0.73 | LMNA (0.60) | LMNASMN1; SMN2TBXAS1KAT2BCYP2D6 | |
| SCHEMBL5231932 | 0.72 | LMNA (0.35) | LMNASMN1; SMN2KAT2BCYP2D6 | |
| SCHEMBL16046329 | 0.71 | ADORA1 (0.52) | ADORA1ADORA3NR1D1ADORA2AHRH3 | |
| SCHEMBL24322161 | 0.70 | ERCC5 (0.36) | LMNASMN1; SMN2KAT2B | |
| SCHEMBL13641556 | 0.69 | ADORA1 (0.41) | ADORA1ADORA3ADORA2ASMN1; SMN2PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587809-B1 | THIENOPYRIDAZINONE DERIVATIVE AS MODULATORS OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| US-20060223809-A1 | Thieno [2,3,-d]pyridazin-4(5H)-ones; modulation of autoimmune diseases with T-cell antiproliferatives; antiinflammatory; organ transplant rejection; AIDS; chronic obstructive pulmonary disease (COPD); asthma | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-10-05 | — | — | US | disclosed |
| US-20060052380-A1 | Thieno [2,3,-d]pyridazin-4(5H)-ones; modulation of autoimmune diseases with T-cell antiproliferatives; antiinflammatory; organ transplant rejection; AIDS; chronic obstructive pulmonary disease (COPD); asthma | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223809-A1 | Thieno [2,3,-d]pyridazin-4(5H)-ones; modulation of autoimmune diseases with T-cell antiproliferatives; antiinflammatory; organ transplant rejection; AIDS; chronic obstructive pulmonary disease (COPD); asthma | CD4, IL5, CCR6 | ADORA1 446/4885ADORA3 387/4885NR1D1 1211/4885 |
| US-20060052380-A1 | Thieno [2,3,-d]pyridazin-4(5H)-ones; modulation of autoimmune diseases with T-cell antiproliferatives; antiinflammatory; organ transplant rejection; AIDS; chronic obstructive pulmonary disease (COPD); asthma | CD4, IL5, CCR6 | ADORA1 446/4885ADORA3 387/4885NR1D1 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.